With cure rates of childhood acute lymphoblastic leukemia (ALL) exceeding 85%, there is a need to mitigate treatment toxicities that can compromise quality of life, including peripheral neuropathy from vincristine treatment.
C ancer remains the leading cause of death by disease in US children despite major advances in the last 20 years. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and as cure rates have surpassed 85%, 1, 2 it becomes increasingly important to mitigate the acute and chronic toxicities of treatment that adversely affect quality of life and longevity. Vincristine is one of the most widely used and effective anticancer agents for treating leukemias, lymphomas, brain tumors, and solid tumors in both adults and children 1, 2 and is administered multiple times as part of treatment protocols for every child with ALL and for children with neuroblastoma, Wilms tumor, rhabdomyosarcoma, Ewing sarcoma, and retinoblastoma. 3 Vincristine exerts its cytotoxic effects by interfering with microtubule formation and mitotic spindle dynamics, leading to mitotic arrest and cell death. [4] [5] [6] The dose-limiting toxic effect of vincristine is peripheral neuropathy, 7, 8 characterized by neuropathic pain and sensory and motor dysfunction (eg, impaired manual dexterity, balance and deep tendon reflexes, a n d a l t e r e d g a i t ) . A substantial percentage of patients develop neuropathy that causes considerable morbidity and often disrupts curative treatment. 9 Currently, there are no reliable means of identifying patients at high risk of vincristineinduced neuropathy nor strategies to mitigate this drug toxicity. Although prior studies have documented racial differences in the incidence of vincristine neuropathy, candidate gene studies have failed to identify consistent genetic variants associated with an increased risk of vincristineinduced neuropathy. [9] [10] [11] [12] To determine whether there are genetic polymorphisms associated with vincristine-induced neuropathy, we performed a genome-wide association study (GWAS) in 2 independent cohorts of children receiving protocol-defined treatment for ALL.
Methods

Patients and Treatment Regimens
Two independent patient cohorts were treated either by St Jude Children's Research Hospital or the Children's Oncology Group (COG) according to contemporary institutional review boardapproved ALL protocols that prospectively assessed and graded vincristine neuropathy according to National Cancer Institute (NCI) criteria. We analyzed all consenting patients who had germline DNA available for genome-wide single-nucleotide polymorphism (SNP) analyses in May 2011. The first cohort included children with newly diagnosed ALL enrolled and treated in the St Jude Total XIIIB protocol [13] [14] [15] (available from the authors). The second cohort included patients with relapsed ALL enrolled in the COG AALL0433 protocol (https://clinicaltrials .gov/show/NCT00381680). Written informed consent was obtained from patients or their guardians and assent from patients, as appropriate. The St Jude Total XIIIB protocol was divided into 3 phases: 8 weeks of remission induction therapy, 2 weeks of consolidation therapy, and 120 weeks of continuation therapy (including a reinduction phase at weeks [16] [17] [18] [19] [20] [21] . Vincristine was administered as a component of combination chemotherapy during the induction and continuation phases of therapy at a dose of 1.5 mg/m 2 with a maximum dose of 2 mg. Altogether, St Jude patients were scheduled to receive a total of 36 vincristine doses. Consecutive patients were enrolled between August 1994 and July 1998 and were followed up for toxic effects through 2001. The COG AALL0433 protocol was a cooperative groupwide phase 3 randomized study of intensive therapy for patients with recurrent childhood precursor B-cell ALL, including late bone marrow or combined relapse (≥36 months since diagnosis), or early (<18 months since diagnosis) isolated extramedullary relapse in the central nervous system or testes. The COG AALL0433 treatment was divided into induction, intensification (with a reinduction phase at weeks 28-32 or 29-33), and continuation phases. Vincristine was administered as a component of combination chemotherapy during the induction, intensification, reinduction, and continuation phases of therapy; a total of 39 doses of vincristine were scheduled to be given per this protocol. Patients were randomly assigned to receive a vincristine dose of 1.5 mg/m 2 with a maximum dose of 2 mg (group A) or 2 mg/m 2 with a maximum dose of 2.5 mg (group B).
Group B treatment and the vincristine dose randomization were permanently suspended by COG in 2010 because of a high incidence of peripheral neuropathy, most prominently in patients aged 13 years or older. Patients were enrolled between March 2007 and September 2010 at the time of the suspension of group B treatment and were followed up for toxic effects through May 2011. As part of required clinical trial adverse event monitoring, children in both cohorts were prospectively assessed for the presence of peripheral neuropathy via physical examination by the treating oncologist at each clinic visit during treatment. 16, 17 Children in the St Jude cohort were assessed for toxicity weekly throughout all phases of therapy. Children in the COG cohort were assessed for toxicity weekly throughout the first year of therapy and monthly thereafter. 
Cellular Analyses
The human precursor B leukemia cell line Nalm6, the human T-lineage leukemia cell line CEM, and the neuroblastoma cell line SH-SY5Y were cultured in RPMI 1640 medium containing 2 mM of glutamine and 10% (vol/vol) fetal bovine serum at 37°C (98.6°F) with 5% CO 2 . iCell neurons derived from human induced pluripotent stem cells were obtained from Cellular Dynamics International and maintained per manufacturer's protocol. Primary ALL cells were isolated by applying a Ficoll-Hypaque gradient to bone marrow aspirates obtained at diagnosis (with a median of 97% blast cells). CEP72 expression (GenBank BC001750) was impaired by using short hairpin RNA. In vitro drug sensitivity of primary ALL cells and of Nalm6 and CEM cell lines was determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazoliumbromide) assay as previously reported. 21 The drug concentration lethal to 50%
of the leukemia cells (LC 50 ) was used as the measure of sensitivity to vincristine. Vincristine-induced neurotoxicity in iCell neurons was determined by individual cell measurements of total neurite outgrowth, number of processes, and number of branches in 1000 cells for each replicate experiment. Luciferase assays to measure CEP72 expression were performed as described in eAppendix 1 in the Supplement. Gene expression of HapMap cells measured by the Affymetrix GeneChip Human Exon 1.0 ST Array was downloaded from http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE7761.
Statistical Analysis
Analyses were conducted using R (http://www.r-project.org/) and SAS (SAS Institute Inc) software. Weighted logistic regression model fitting for recurrent events was used to test the associations between SNP genotypes and the phenotype of peripheral neuropathy (ie, occurrence of grade ≥2 vincristineinduced neuropathy during continuation therapy), including cumulative vincristine dose and genetically determined ancestry as covariates, as previously described (eAppendix 1 in the Supplement). 15 After filtering out SNPs with a call rate of less than 95% (SNP call rate is the percentage of patients who have a confident genotype call for each SNP according to Affymetrix quality control criteria) or minor allele frequency of less than 1%, the remaining SNPs (484 623 typed SNPs and 1 091 393 imputed SNPs) were assessed in a GWAS for their association with vincristine-induced neuropathy in the St Jude and COG cohorts separately using weighted logistics regression models, then combined by pooling the P values from the 2 cohorts via the Fisher combined probability test. All P values were computed using 2-sided tests; statistical significance was determined at the genome-wide significance level of P<5×10 −8 . Post-GWAS analyses focusing on the CEP72 SNP rs924607 were performed as follows: the relationship between the time to first episode and genotype was analyzed using cumulative incidence function estimates 22 
Results
Patient Population
Genome-wide SNP analysis and vincristine-induced neuropathy were assessed in 321 patients enrolled in 2 ALL treatment protocols. Of 247 consecutive patients enrolled in the St Jude Total XIIIB protocol, 222 patients with newly diagnosed ALL (median age at diagnosis, 6.0 years; range, 0.1-18.8 years) had germline DNA available for analysis and were included in this study (eFigure 1 in the Supplement). Of the 137 patients who were enrolled in the COG AALL0433 protocol, 99 patients with relapsed ALL (median age at diagnosis, 11.4 years; range, 3.0-23.8 years) had germline DNA available for analysis and were included in this study (eFigure 2 in the Supplement). The demographic and clinical characteristics of these 321 patients are summarized in Table 1 and for each cohort in eTables 3 and 4 in the Supplement.
Vincristine-Associated Neurotoxicity
Grade 2 to 4 vincristine-induced peripheral neuropathy during continuation therapy occurred in 28.8% (64/222) and 22.2% (22/99) of patients in the St Jude and COG protocols, respectively. Genetically determined ancestry and vincristine cumulative dose were the demographic or clinical characteristics significantly related to the occurrence of vincristineinduced neuropathy in each of the cohorts, as summarized in eTables 3 and 4 in the Supplement. Within the COG trial, the
Meta-analysis of Genome-wide Association Results
Assessing SNPs that had a P<.05 in both cohorts and concordant effects in both populations yielded 5051 typed SNPs and 10 195 imputed SNPs. The Manhattan plot (eFigure 3 in the Supplement) depicts P values of SNPs from the 2 patient cohorts assessed via a meta-analysis. The SNPs with the lowest P values for their association with vincristine-induced neuropathy in the 2 cohorts are summarized in Table 2 and in eTable 5 in the Supplement. In a multivariable analysis that included genetically defined ancestry and cumulative dose of vincristine, only rs924607 remained genome-wide significantly (P = 4.7×10 −8 ) related to the development of vincristineinduced neuropathy (Table 2 and eTable 5). rs924607 is in the promoter region of the CEP72 gene in chromosome 5 ( Figure 1) .
Twenty (62%) of 32 patients with the TT genotype in the St Jude cohort and 8 (44%) of 18 patients with the TT genotype in the COG cohort developed at least 1 episode of vincristine-induced neuropathy. In total, 28 of 50 patients (56%) with the TT genotype developed at least 1 episode of grade 2 to 4 vincristine-induced neuropathy ( Table 3 ) compared with 58 (21.4%) of 271 patients with the CC or CT genotype (P = 2.4×10 −6 ). The allelic odds ratios for the development of Association of CEP72 rs924607 Genotype With Development, Onset Time, and Severity of Vincristine-Induced Peripheral Neuropathy
The cumulative incidence of all neuropathy episodes (grade 2-4) differed significantly by CEP72 rs924607 genotype (diplotype) in both patient cohorts treated with 1.5 mg/m 2 of vincristine, with P values in the St Jude, COG, and combined cohorts of P < .0001, P = .0087, and P < .0001, respectively, by Gray test (Figure 2 , A-C). Likewise, the cumulative incidence of severe neuropathy episodes (grades 3-4) was also significantly higher in patients homozygous for the CEP72 risk allele (P < .0001) ( Figure 2D Severe (grade 3-4) neuropathy in combined cohorts
D
The cumulative incidence of vincristine-induced neuropathy (grades 2-4) differed by CEP72 promoter SNP (rs924607) genotype in the St Jude cohort (A) (P < .0001), the Children's Oncology Group (COG) group A cohort (B) (P = .0087), and the combined St Jude and COG group A cohort (C) (P < .0001). Likewise, the cumulative incidence of severe neuropathy (grades 3-4) was also significantly higher in patients homozygous for the CEP72 risk allele (TT) (D).
P values were computed based on weighted logistic regression adjusting for ancestry and accounting for multiple episodes of neuropathy. The number of patients evaluable and at risk of neuropathy is provided for each CEP72 genotype (diplotype). The x-axis represents time since the start of continuation therapy for ALL.
genotype, cumulative vincristine dose, and genetically determined ancestry as explanatory variables, the estimated ratio of median time to the first episode of neuropathy in patients with a TT genotype compared with patients with a CT or CC genotype was approximately 20% shorter in TT patients of any race and at any cumulative vincristine dose level (P = 6.19×10 −6 for the regression coefficient of the SNP) (eTable 8 in the Supplement 
Rs924607 and CEP72 mRNA Expression
Because rs924607 is located in the promoter region of CEP72, we examined CEP72 messenger RNA (mRNA) expression levels for association with rs924607 genotype in HapMap samples (CEU), using the publicly available gene expression data set. 24 Patients who were homozygous for the variant T allele had significantly lower expression of CEP72 mRNA compared with those who were heterozygous or homozygous for the wild-type C allele (P = .03) (eFigure 6A in the Supplement). The effect of rs924607 genotype on CEP72 expression was confirmed using a luciferase reporter assay in 2 different human cell lines, documenting significantly lower expression with the T allele compared with the C allele in both SH-SY5Y neuroblastoma cells (eFigure 6B in the Supplement) and Nalm6 leukemia cells (eFigure 6C in the Supplement). The rs924607 T variant creates a consensus binding site for the NKX-6.3 transcription factor (repressor) (eFigure 6, D-H and eTable 10 in the Supplement), markedly enhancing NKX-6.3 binding to the risk allele, leading to lower CEP72 mRNA expression.
Low CEP72 Expression and Vincristine-Induced Toxicity
The relationship between CEP72 expression and vincristineinduced neurotoxicity was assessed in neurons derived from human induced pluripotent stem cells (iPSCs), revealing significantly greater sensitivity to vincristine when CEP72 expression was reduced (eFigure 7, A-B in the Supplement). Likewise, reducing expression of CEP72 in 2 human ALL cells lines, Nalm6 (B-cell lineage) (eFigure 7C in the Supplement) and CEM (T-cell lineage) (eFigure 7E), was associated with increased sensitivity to vincristine (eFigure 7, D and F). Moreover, primary leukemia cells from patients with newly diagnosed ALL who were homozygous for the CEP72 risk allele (TT) (mean LC 50 , 0.9 μM; 95% CI, −0.5 to 2.3 μM) were more sensitive to vincristine compared with patients with either the CT (mean LC 50 , 2.6 μM; 95% CI, 0.6-4.7 μM) or CC (mean LC 50 , 11.9 μM; 95% CI, 3.0-20.7 μM) CEP72 genotype (P = .02) (eFigure 7G).
Discussion
This study found that an inherited variant in the promoter region of the CEP72 gene was associated with a higher incidence and severity of vincristine-related peripheral neuropathy in children with ALL, with the cumulative incidence of neuropathy significantly higher and the mean grade of neuropathy significantly greater in patients homozygous for the CEP72 risk allele (TT) compared with all other patients. The CEP72 gene encodes a centrosomal protein that is essential for microtubule formation, and vincristine exerts its pharmacologic effects by inhibiting microtubule formation. We found that the CEP72 variant associated with vincristine neuropathy (T allele at rs924607) creates a binding site for a transcriptional repressor, leading to lower CEP72 mRNA expression, and we showed that reducing the expression of CEP72 in human iPSC neurons or leukemia cells increased their sensitivity to vincristine. Because vincristine-induced toxicity can be influenced by cumulative dose of vincristine and can differ by race, we included both cumulative dose and ancestry as covariates in our analyses, revealing that the CEP72 rs924607SNP was the only SNP reaching genome-wide significance (<5×10 −8 ) in its association with vincristine-induced neuropathy. The frequency of the risk allele (T) was lower in African American patients compared with other racial groups, consistent with its lower frequency in African ancestry samples in the HapMap collection. This finding is also consistent with the reported lower incidence of vincristine-induced neuropathy in black patients. 25 We found that children who inherited 2 copies of the CEP72 risk allele (homozygous for T at rs924607) had a significantly higher incidence of vincristine-induced peripheral neuropathy (60.8% [95% CI, 43.9%-77.6%] in patients with the TT genotype compared with 23.4% [95% CI, 17.4%-29.4] in patients with the CC/CT genotype). We also found that patients with CEP72 TT had increased severity (grade) of toxicity at first episode (2.4-fold [95% CI 1.6-3.7] higher grade of neuropathy for TT vs CT/CC) at any given cumulative dose of vincristine. Vincristine is widely used to treat leukemia, lymphoma, various solid tumors, and brain tumors in children and adults. 26 given, 29 and the types of symptoms captured. 9 In the current study, patients received uniform treatment according to prospective clinical trial protocols, with neuropathy assessed by NCI criteria to prospectively identify all patients who developed grades 2 to 4 neuropathy during continuation therapy with vincristine. Although a genetic component of vincristineinduced neuropathy would be consistent with previously reported racial differences in the incidence of vincristineinduced neuropathy, 25 previous candidate gene studies have not yielded reproducible findings. We therefore took an agnostic genome-wide approach to identify genetic variants influencing vincristine-induced peripheral neuropathy, revealing the previously unrecognized association with CEP72 genotype.
The current study has limitations, including the small sample size (n = 321), the small number of patients homozygous for the CEP72 risk allele (n = 50; approximately 16% of patients), and our assessment of children only in the context of ALL chemotherapy. However, our clinical findings are corroborated by multiple lines of laboratory evidence in human iPSC neurons and leukemia cells and, if verified in additional patient populations, could lead to a new approach for identifying patients at high risk of vincristine-related neuropathy. Because our data suggest that the leukemia cells of patients who are homozygous for the CEP72 risk allele are more sensitive to vincristine, it may be possible to treat these patients with a lower dose of vincristine to decrease the risk or severity of neuropathy without compromising the antileukemic effects of vincristine, a possibility that merits assessment in future clinical trials.
Conclusions
In this preliminary study of children with ALL, an inherited polymorphism in the promoter region of CEP72 was associated with increased risk and severity of vincristine-related peripheral neuropathy. If replicated in additional populations, this finding may provide a basis for safer dosing of this widely prescribed anticancer agent.
